CAMBRIDGE, MA., – January 7, 2024 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with Nasdaq Live from MarketSite to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies by gaining an unprecedented understanding of immune dysregulation at the single cell level. HiFiBiO’s unique high-resolution translational DIS® platform enhances the probability of success in delivering these innovative immunotherapies to patients.

Nasdaq Listings Host Kristina Ayanian delves into companies’ notable accomplishments, industry trends, and the driving factors behind their success through engaging conversations with C-suite executives and industry leaders.

Listen to the full interview here:

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage global biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases.  HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches.  Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com

HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiO and its affiliates.